PS
Therapeutic Areas
Lantern Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LP-300 | Non-Small Cell Lung Cancer (NSCLC) - Never smokers with relapsed advanced primary adenocarcinoma | Phase 2 |
| LP-184 | DNA Damage Repair (DDR) Deficient Cancers | Phase 1 |
| LP-284 | DNA Damage Repair (DDR) Deficient Cancers; Soft Tissue Sarcoma | Phase 1 |
| ADC Program | Undisclosed (12 cancer indications) | Preclinical |